Art. -Nr.: HY-137506

XST-14

4 Cited Publications

Kundenbewertung

Based on 4 publication(s) in Google Scholar

XST-14 is a potent, competitive and highly selective ULK1 inhibitor with an IC₅₀ of 26.6 nM. XST-14 induces autophagy inhibition by reducing the phosphorylation of the ULK1 downstream substrate. XST-14 induces apoptosis in hepatocellular carcinoma (HCC) cells and has antitumor effects.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.26%
CAS. Nr.: 2607143-50-8
Formel: C₁₆H₂₁NO₄
Molecular Weight:291.34

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

XST-14 Chemical Structure

CAS. Nr.: 2607143-50-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

CaMK II

ULK1

26.6 nM (IC₅₀)

Alle ULK Isoform-spezifische Produkte anzeigen :

ULK1
ULK2

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

Alle TGF-β Receptor Isoform-spezifische Produkte anzeigen :

Alle CaMK Isoform-spezifische Produkte anzeigen :

In Vitro

XST-14 inhibits ULK1 (IC₅₀=13.6 nM), MAP2K1/MEK1 (IC₅₀=721.8 nM), MAPK14/p38 alpha (IC₅₀=283.9 nM), TGFBR2 (IC₅₀=809.3 nM), ACVR1/ALK2 (IC₅₀=183.8 nM), ULK2 (IC₅₀=70.9 nM) and CAMK2A (IC₅₀=66.3 nM) by the 10-point titration results from SelectScreen Kinase Profiling Services^[1].
XST-14 (20-80 μM; for 24 h) leads a decrease in cell proliferation activity^[1].
XST-14 (5 μM; for 24 h) induces apoptosis in HepG2 and human primary HCC cells^[1].
XST-14 (5 μM; for 12 h) strongly inhibits the conversion of LC3-I to LC3-II in CHO cells stably expressing GFP-LC3^[1].
XST-14 (5 μM; for 12 h) inhibits the Ser249 phosphorylation of PIK3C3 and Ser15 phosphorylation of BECN1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

HepG2 cells
Concentration:

20, 40, 60, 80 μM
Incubation Time:

24 hours
Result:

Led a decrease in cell proliferation activity.

Apoptosis Analysis^[1]

Cell Line:

HepG2 and human primary cells
Concentration:

5 μM
Incubation Time:

24 hours
Result:

Induced apoptosis in HepG2 and human primary HCC cells.

Cell Autophagy Assay^[1]

Cell Line:

CHO, HepG2 cells stably expressing GFP-LC3
Concentration:

5 μM
Incubation Time:

12 hours
Result:

Strongly inhibited the conversion of LC3-I to LC3-II in CHO cells.
Dramatically decreased the number of GFP-LC3 puncta in HepG2 cells.
Decreased autophagosome formation and blocked autophagosome/lysosome fusion in HepG2 cells.

Western Blot Analysis^[1]

Cell Line:

HepG2 cells
Concentration:

5 μM
Incubation Time:

12 hours
Result:

Inhibited the Ser249 phosphorylation of PIK3C3 and Ser15 phosphorylation of BECN1.

In Vivo

XST-14 (15, 30 mg/kg/day; IP; for 4 consecutive weeks) displays anti-HCC efficacies, resulting in decreased tumor weights and suppressed tumor growth of HCC cells in nude mice^[1].
XST-14 (2 mg/kg for IV; 10 mg/kg for IP) has a T_1/2 of 2.31 hours for IV and a T_1/2 of 2.69 hours for IP^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Nude mice bearing HepG2 tumor xenografts^[1]
Dosage:

15, 30 mg/kg
Administration:

IP; daily; for 4 consecutive weeks
Result:

Displayed anti-HCC efficacies, resulting in decreased tumor weights and suppressed tumor growth of HCC cells in nude mice.

Animal Model:

Sprague-Dawley rat^[1]
Dosage:

2 mg/kg for IV; 10 mg/kg for IP (Pharmacokinetic Analysis)
Administration:

IV or IP
Result:

Had a T_1/2 of 2.31 hours, a CL of 26.28 mL/min•kg, and and an AUC of 1269 hr•ng/mL for IV.
Had a T_1/2 of 2.69 hours, a C_max of 2033 ng/mL, and an AUC of 5979 hr•ng/mL for IP.

Chemical Information

CAS. Nr. 2607143-50-8
Appearance Solid
Molecular Weight 291.34
Formel C₁₆H₂₁NO₄
Color White to off-white
SMILES

O=C(OC)C1=CC2=C(OC(C)C)C=C(OC(C)C)C=C2N1
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (4)

All

Sort by:

Journal Impact Factor

Nat Aging

Reduced ULK1 links impaired autophagy and mitophagy to Alzheimer's disease pathology. [Abstract]

2026 May 14. PMID: 42135576
Cancer Res

Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. [Abstract]

2026 Jul 2;86(13):3194-3212. PMID: 42008004
Toxins

The Mycotoxin De-Epoxy-Deoxynivalenol (DOM-1) Increases Endoplasmic Reticulum Stress in Ovarian Theca Cells. [Abstract]

2023 Mar 17;15(3):228. PMID: 36977119
National Autonomous University of Mexico

2025.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 250 mg/mL (858.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4324 mL

17.1621 mL

34.3242 mL

5 mM

0.6865 mL

3.4324 mL

6.8648 mL

10 mM

0.3432 mL

1.7162 mL

3.4324 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (7.14 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (7.14 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Si-Tu Xue, et al. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target . Autophagy. 2020 Oct;16(10):1823-1837. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.4324 mL	17.1621 mL	34.3242 mL	85.8104 mL
	5 mM	0.6865 mL	3.4324 mL	6.8648 mL	17.1621 mL
	10 mM	0.3432 mL	1.7162 mL	3.4324 mL	8.5810 mL
	15 mM	0.2288 mL	1.1441 mL	2.2883 mL	5.7207 mL
	20 mM	0.1716 mL	0.8581 mL	1.7162 mL	4.2905 mL
	25 mM	0.1373 mL	0.6865 mL	1.3730 mL	3.4324 mL
	30 mM	0.1144 mL	0.5721 mL	1.1441 mL	2.8603 mL
	40 mM	0.0858 mL	0.4291 mL	0.8581 mL	2.1453 mL
	50 mM	0.0686 mL	0.3432 mL	0.6865 mL	1.7162 mL
	60 mM	0.0572 mL	0.2860 mL	0.5721 mL	1.4302 mL
	80 mM	0.0429 mL	0.2145 mL	0.4291 mL	1.0726 mL
	100 mM	0.0343 mL	0.1716 mL	0.3432 mL	0.8581 mL

XST-14

4 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

XST-14

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Neuronal Signaling Compound Library

Protein Tyrosine Kinase Compound Library

TGF-beta/Smad Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) XST-14

Alle ULK Isoform-spezifische Produkte anzeigen

Alle p38 MAPK Isoform-spezifische Produkte anzeigen

Alle TGF-β Receptor Isoform-spezifische Produkte anzeigen

Alle CaMK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (4)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

XST-14 Related Classifications

HY-137506 Related Classifications